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Universal antenatal human
immunodeficiency virus testing in
Hong Kong: consensus statement
Following the recommendations of the Advisory Council on AIDS,
Hong Kong, the Hospital Authority announced plans to introduce
universal antenatal screening for human immunodeficiency virus
infection and hence, a consensus conference was held to discuss
strategies for implementing such screening in Hong Kong. This paper
reports the discussions of the consensus conference. The consensus
meeting group consisted of 15 clinicians and scientists from Hong
Kong, Macau, and Thailand. Seven commonly asked questions
concerning mother-to-child transmission of human immunodeficiency
virus were selected for discussion by the participating panellists.
Information on the laboratory diagnosis of human immunodeficiency
virus infection and the efficacy of preventive measures in reducing
mother-to-child transmission of human immunodeficiency virus were
reviewed. Data from local studies was also presented and discussed.
The timing, potential problems, and cost issues involved in testing all
pregnant women in Hong Kong for human immunodeficiency virus
were then considered.
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Introduction
Human immunodeficiency virus (HIV) is the cause of acquired
immunodeficiency syndrome (AIDS). It is now known that there are three
main routes of HIV transmission: sexual activity; exposure to contaminated
blood, commonly referring to the sharing of needles by intravenous drug
users; and mother-to-child transmission (MTCT). While behavioural
intervention is the main strategy to minimise HIV infection through sexual
activity and needle-sharing, medical advances have contributed to the
reduction in MTCT of the infection.
The landmark study PACTG 076, showed that antepartum, intrapartum,
and postnatal zidovudine (AZT) treatment could effectively reduce the
MTCT rate of HIV by two thirds.1 This led to various studies on the
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optimum duration of AZT treatment and trials of
other antiretroviral agents. Antiretroviral regimens
investigated and their efficacy are summarised in the
Table. This research interest also led to the establish-
ment of recommendations for universal antenatal HIV
screening in the US in 1995,2 and in the UK in 1998.3
More recently, the US Public Health Service has
revised these recommendations, strongly recommend-
ing universal HIV testing for all pregnant women.4
In Hong Kong, HIV infection is still relatively un-
common in women, with a cumulative total of 265
cases (17.2% of the total of 1542) reported at the end
of 2000.5 In an unlinked anonymous screening program
conducted by the Department of Health, the prevalence
of HIV infection among pregnant mothers was
0.03%. A similar rate of 0.06% was reported in a study
involving over 5000 pregnant women in Kwong Wah
Hospital.6 According to the annual report of the
Hospital Authority (HA), there were 59 250 deliveries
in Hong Kong in 1997 and 52 977 in 1998.7 Henceforth,
this provides an estimate of between 15 to 30 HIV-
positive pregnancies in Hong Kong each year. Assum-
ing the rate of MTCT of HIV is 20%, approximately
three to six babies would be born annually with the
virus, if no intervention were instituted.
In Hong Kong, HIV testing is currently offered
sparingly to pregnant mothers who are considered by
obstetricians to be at risk. Available data indicates
that the opportunity for prevention of MTCT of
HIV was frequently missed by such a strategy. Of 28
babies born to HIV-positive mothers between 1993 to
2000, the HIV status of the mother was unknown in
50% of cases (Department of Health, unpublished
data, 2001). The fact that effective treatment is
available for prevention of an incurable disease
argues strongly for a revision of existing practice. In
late 2000, the Hong Kong Advisory Council on
AIDS proposed the adoption of a new strategy
involving universal testing of all pregnant women on a
voluntary basis.
Process of consensus
The consensus meeting on Universal Antenatal HIV
Testing: Translating Science into Public Health Policy
was held on 21 April 2001, as the third current topic
in infectious diseases organised by the Centre of
Infection, the University of Hong Kong. A panel of
experts from the fields of obstetrics, paediatrics, public
health, and virology was provided with the latest
scientific papers1-5,8-19 and participants were invited
to speak on and discuss various aspects of the topic.
After the formal presentation, a panel discussion
was held with briefing notes (addressing seven
questions) distributed to all meeting attendees. All
attendees participated actively in the discussion, which
was focused on elaboration of the feasibility, cost-
effectiveness, and operational details of universal
antenatal HIV testing in Hong Kong.
Finally, conclusions were drawn on the basis of
current scientific information and the views expressed
by the panel and other participants.
Table. Clinical trials of antiretroviral agents for the prevention of mother-to-child transmission of human
Study Regimen Antepartum
14-28 weeks 29-36 weeks > 36 weeks
PACTG 0761 ZDV†
Thai19 ZDV
Cote d’Ivoire18 ZDV
DITRAME17 ZDV
Wade24 ZDV
ZDV
ZDV
ZDV
Global Strategies21 ZDV + 3TC‡
ZDV + 3TC
ZDV + 3TC
PETRA Arm A23 ZDV + 3TC
PETRA Arm B23 ZDV + 3TC
PETRA Arm C23 ZDV + 3TC
Blanche20 ZDV + 3TC
ZDV
HIVNET22 ZDV or NVP§
* Shaded area indicates period of treatment with antiretroviral agents
† ZDV zidovudine
‡ 3TC lamivudine
§ NVP nevirapine
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Questions and discussion
Do we have a robust test to reliably determine the
human immunodeficiency virus infection status of
the mother and the baby?
In adults, the most effective and common way to
determine whether a person is suffering from HIV
infection is through detection of HIV antibodies.
Hong Kong follows testing guidelines and procedures
agreed internationally. The HIV enzyme-linked
immunosorbent assay (ELISA) is generally used as a
screening test and is available at the Government Virus
Unit of the Department of Health, and some HA
hospitals and private laboratories. The Government
Virus Unit also provides confirmatory testing using
the Western blot technique. Most of the commercially
available ELISA kits have a sensitivity and specificity
greater than 99%. Due to the impact of a diagnosis of
HIV infection, however, testing for HIV antibodies is
only reported as positive when a repeatedly reactive
ELISA test is confirmed by a more specific assay, such
as the Western blot technique.
In neonates and infants younger than 1 year old,
transfer and persistence of maternal antibodies
complicates the diagnosis of HIV infection. Other
techniques for the diagnosis of HIV infection include
p24 antigen detection, isolation of HIV by culture,
and the polymerase chain reaction (PCR). Studies
have shown that PCR is by far the most sensitive
and timely method for diagnosing HIV infection. The
US Center for Disease Control and Prevention recom-
mended in 1998 that diagnostic testing should be
performed at the following ages: 48 hours, between 1
and 2 months, and between 4 and 6 months.4 A positive
PCR test should be confirmed by a repeat virologic
test on a second specimen. Although HIV DNA PCR
was initially reported as the preferred virologic method,
subsequent studies have shown that HIV RNA
amplification is more sensitive than DNA PCR for
early diagnosis of perinatal infection in infants
exposed to HIV. Extracellular HIV RNA appears
soon after infection and the viral load is much higher
than the detection limit of quantitative HIV RNA.
Quantitative HIV RNA is available in Hong Kong and
is used currently to diagnose paediatric cases.
Is there evidence that  knowledge of the human
immunodeficiency virus status would be beneficial
to the mother and the baby?
Early diagnosis of HIV infection has a number of
benefits. Firstly, it allows counselling and assessment
before the disease manifests at an advanced stage as
AIDS. With the advent of highly active antiretroviral
therapy, there is increasing evidence that the prognosis
in terms of quality of life and survival can be improved
by timely treatment. Secondly, knowledge of HIV
status allows the mother to make informed choices
about the management of her pregnancy. Thirdly,
it provides an opportunity for prevention of MTCT
of HIV infection.
Several studies have shown that good obstetric care
combined with antiretroviral prophylaxis can reduce
the risk of perinatal HIV infection by about two
thirds.1,17-23 The US has seen a dramatic reduction
 immunodeficiency virus*
Intrapartum Postpartum Relative efficacy (% reduction in transmission)
1 week 2-6 weeks
Infant 67.5
50.3
43.8
Mother 34.5
Infant 77.0
Infant 62.4
Infant <48 hrs 65.0
Infant >72 hrs 30.8
Infant 47.1
Infant 44.5
Infant 47.7
Mother and infant 52.0
Mother and infant 40.0
0
Infant 2.6
Infant 6.5
Infant Transmission rate 25.1% (ZDV) vs 13.1% (NVP)
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in the MTCT of HIV, following the launch of a
programme in 1995 consisting of routine counselling
and voluntary testing of pregnant women for HIV,
and offering antiretroviral prophylaxis to infected
women during pregnancy and delivery, and for the
infant after birth. To maximise MTCT prevention
efforts, women must be identified with HIV infection
early in pregnancy to allow prompt initiation of
antiretroviral prophylaxis. Studies of antiretroviral
prophylaxis regimens17-24 support selection of the
PACTG 076 study regimen, which commenced AZT
therapy at 14 weeks of gestation, and achieved a
67.5% to 77.1% relative reduction in the risk of HIV
transmission (Table).1,24 Besides offering chemo-
prophylaxis, the mother could also be counselled
regarding methods of delivery and baby feeding. The
risk of MTCT attributable to breastfeeding is estimated
at between 7% and 22%.25,26 In one study, delivery by
Caesarean section and avoidance of breastfeeding
were shown to reduce the rate of MTCT from 25% to
less than 5%.15 Finally, for babies known to be born
to an HIV-infected mother, appropriate assessment
and evaluation can be arranged to allow early diag-
nosis of paediatric HIV infection and initiation of
prophylaxis to prevent life-threatening Pneumocystis
carinii pneumonia.
Is the provision of universal antenatal human
immunodeficiency virus testing an acceptable
strategy for the pregnant women?
Before any new antenatal screening test is introduced,
the opinions of pregnant women should be considered.
This is particularly true for HIV testing. Studies
conducted overseas showed that women were
generally in favour of a test offer and were more
concerned about having an unhealthy baby. Routine
testing rather than a selective protocol was preferred
by many as it eliminated the stigma of agreeing to
testing.
A study conducted at Kwong Wah Hospital in 1999,
saw 5597 pregnant women offered the screening test,
with 97.5% of the women accepting the offer.6 A further
study conducted at Tsan Yuk Hospital, concerned the
acceptance and attitude towards universal antenatal
HIV antibody screening (Li CFI, unpublished data,
2001). Seventy-two percent of pregnant women
(n=537) agreed that the test should be offered, and 54%
indicated they would accept the test if offered.
Acceptance was correlated positively with perceived
risk of infection. In this particular study, it was also
documented that more than 80% of women felt there
was inadequate information available in Hong Kong
on antenatal HIV infection.
Do we have the health infrastructure to implement
universal antenatal human immunodeficiency
virus testing in Hong Kong?
There are between 50 000 and 60 000 births every year
in Hong Kong. Almost all births occur in hospitals and
more than 90% of pregnant women now receive
antenatal care. As part of routine antenatal care,
pregnant women are currently counselled and screened
for various conditions, including syphilis, rubella,
hepatitis B status, and thalassaemia. Thus, it would be
more feasible to introduce universal antenatal HIV
testing as part of the antenatal screening programme,
rather than as a separate test. Provision of key infor-
mation on HIV infection and MTCT would also be
required before and after testing.
Currently, various units in HA hospitals and the
Department of Health are designated for and are
experienced in providing care for patients who are
HIV-positive or have AIDS. As there are relatively few
HIV-positive mothers, they can be referred to these
pre-existing units to continue their care. Nonetheless,
there must be a territory-wide monitoring system to
follow up all HIV-infected mothers to document their
management and outcome. Babies delivered, whether
infected or not, should also be monitored by this
territory-wide system.
What is the additional cost involved in the
implementation of universal antenatal testing? Are
we justified in introducing the programme with
respect to the costing implications?
In the US, the costs of universal HIV screening are
considered to be low, and the benefits high. Assuming
that the marginal cost of adding an ELISA test to the
existing prenatal panel of tests is HK$24 per woman,
and the prevalence of HIV in pregnant women is 2
per 10 000, then the cost of routine prenatal testing
per HIV-positive woman identified would be
HK$120 000.15 Similarly, universal screening with
pre-test discussion was estimated to be cost-effective
in the UK, particularly in London where the prevalence
of HIV infection among pregnant women was 0.19%.
Elsewhere in the UK, where the infection is less
prevalent (0.02%), a universal screening program was
deemed cost-effective only if the uptake was above
90%.13
There is a lack of good local data on the cost-
effectiveness of the test. Nonetheless, no local data on
the cost-effectiveness of universal antenatal syphilis
and rubella screening tests were available before
implementation of such screening in Hong Kong.
Perhaps the question should be whether the cost of the
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screening programme is affordable and reasonable.
The laboratory cost for screening all pregnant women
for HIV was estimated to be HK$1.6 million annually.
Assuming a prevalence of 3 cases in 5000 and an uptake
of 90%, the laboratory cost per HIV-positive woman
identified would be HK$59 000. Compared with
the cost of universal screening of blood (HK$430 000)
to prevent one transmission of HIV via blood trans-
fusion,27 the cost of universal, voluntary antenatal HIV
screening seems reasonable.
Is this the right time to introduce the programme?
Are we too early, or are we late and why?
In the US, universal HIV testing of pregnant women
commenced in 1995, shortly after the publication of
the PACTG 076 study. Recently, the recommendations
were updated, emphasising that universal HIV testing
with patient notification be a routine component of
prenatal care.4,15 In the UK, an intercollegiate working
party for enhancing voluntary confidential HIV testing
during pregnancy was convened and the programme
implemented in 1998.3 According to the Department
of Health (UK), the target is to increase uptake of
antenatal HIV testing to 90%, and identification of
HIV-infected pregnant women to 80% nationally by
the end of 2002, offering this latter group advice
and treatment during antenatal care. It is anticipated
that these targets will result in an 80% reduction in
the number of children with HIV acquired from an
infected mother during pregnancy, birth, or through
breastfeeding.3
Routine HIV testing during pregnancy is being
implemented in many other European countries. A
consensus statement from a pan-European group has
recommended that every pregnant woman should, as
of right, have access to HIV testing and information;
and that provision of testing without undue obstacles
should be mandatory for health care providers.28 France
and The Netherlands have further stated that the offer
of maternal HIV testing by health professionals is a
mandatory requirement.29
In Thailand, a universal voluntary HIV counselling
and testing programme has been in place for some years,
with great support from the general public as well as
from the government. In Macau, an unlinked,
anonymous sero-surveillance programme was
introduced in 1997. Since last year, HIV testing has been
offered routinely to all mothers receiving antenatal care
in Macau.
It is, therefore, definitely not too early to introduce
such a programme in Hong Kong. It should not be
implemented hastily, however. Operational details
should be determined. Definite targets should also be
set in order to monitor the uptake, progress, and
effectiveness of the programme implemented.
Are there disadvantages associated with a universal
testing system? Is there a role for an alternative
mechanism?
One alternative to universal testing is selective testing
of those who are identified as high risk for HIV.
Selective testing may stigmatise women, however,
and is liable to miss many of those infected. In the
UK, it has performed poorly.30 If the uptake rate of a
universal programme in Hong Kong were low,
however, a large proportion of HIV-positive women
would still remain undiagnosed. In order to ensure a
high uptake, an ‘opt-out’ strategy where patients
actively decline the test is preferable.
Finally, one must remember that being given a
diagnosis of HIV infection during pregnancy is a
tremendously stressful experience. Support and
counselling should be available on an urgent basis. In
a low prevalence population, the false positive rate
of even a highly sensitive and specific test would
still be substantial. The false positive rate using a
single test on one sample in a local study was 0.24%,
which is higher than the true positive rate of 0.06%.
However, this false positive rate was calculated on the
basis of a single ELISA test. If the standard currently
adopted by the Government Virology Unit of the
Department of Health is followed—that is, testing for
HIV antibodies is only reported as positive when a
repeatedly reactive ELISA test is confirmed by the
Western blot technique—then all false-positive
reporting of the diagnosis would be eliminated.
Conclusion
The HIV prevalence in pregnant mothers in Hong Kong
is estimated to be 0.03% to 0.06%, which is relatively
low compared with other countries. The number of
women diagnosed as HIV-positive, however, is
increasing. As MTCT is a route for the transmission
of HIV, the number of children with HIV can also be
expected to increase.
Research conducted since 1994 indicates that
MTCT can be reduced by a number of interven-
tions.1,17-23 These include termination of pregnancy,
early antepartum and intrapartum administration of
antiretroviral agents to HIV-positive mothers and to
babies postnatally, delivery by caesarean section,
good obstetric care, and avoidance of breastfeeding.
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The success of these measures, however, hinges on
the very first step of identifying HIV-positive mothers.
Voluntary universal HIV testing as part of routine
antenatal care has been shown to be effective in
identifying HIV-infected pregnant women and in
reducing MTCT of HIV. This strategy applies to both
high and low prevalence populations, and is effective
in developed as well as resource-poor countries. For
Hong Kong, as the costs of screening are low and the
effectiveness apparently high, such screening appears
cost-effective, and a formal cost-effectiveness study
does not appear necessary.
While the implementation of universal, voluntary
antenatal HIV testing is well founded scientifically,
these principles cannot be translated into practice
without addressing the essential features of an effective
programme. First of all, the operational details should
be determined and the rationale made known to the
community. A vigorous evaluation and monitoring
system for the entire programme should be put in place.
Additional costs required to implement such a system
must be identified, and the resources and structure
necessary assembled before the screening is
introduced. Secondly, health care professionals
involved need to be provided with appropriate training
in the care of HIV-positive pregnant women, their
babies, and family. Thirdly, clinical protocols must be
established based on an ‘opt-out’ approach, where
patients must actively decline screening, in order to
ensure a high uptake. Fourthly, testing should be made
on a voluntary basis after providing patients with
appropriate information. Finally, patient confidentiality
should be protected.
Considering the broader perspective, working
targets are needed and the programme should be
regularly evaluated. Antenatal HIV screening as a
means of prevention of MTCT of HIV is a perfect
example of how health objectives should be established
and priorities considered in context, so as to ensure
effective use of resources. For success, support from
the community and the government will be required.
From the data gathered locally to date, it seems that
there is widespread acceptance among pregnant women
of universal HIV testing as part of antenatal care. It is
also clear that more information on MTCT of HIV
needs to be provided to the public.
The Hong Kong Advisory Council on AIDS recently
recommended that universal antenatal screening be
adopted in Hong Kong and the government has
reaffirmed its support of this policy.16 It is now time for
the medical community to respond to these initiatives.
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